Search
Flecainide
go.drugbank.com/drugs/DB01195ApprovedInvestigationalWithdrawn[A186880] Flecainide’s development began in 1966 and was first synthesized in 1972 as an attempt to generate new anesthetics. … [L8878,L5056] Flecainide was granted FDA approval on 31 October 1985.[L8875]
Synonyms: N-(2-Piperidinylmethyl)-2,5-bis(2,2,2-trifluoroethoxy)benzamideProducts: FLECAINIDE EGIopamidol
go.drugbank.com/drugs/DB08947ApprovedInvestigationalIopamidol is a contrast agent developed by Bracco with nonionic, low-osmolar properties.
Categories: Compounds used in a research, industrial, or household settingProducts: PAMIRAY 370 ENJ. 50 ML 0,755 MG FLAKON, 1 ADET, PAMIRAY 370 ENJ. 100 ML 0,755 MG FLAKON, 1 ADETMometasone
go.drugbank.com/drugs/DB00764ApprovedInvestigationalMometasone is a corticosteroid not currently used in medical products. [Mometasone furoate] however, is still in use.
Products: MOMETASONE EGIcatibant
go.drugbank.com/drugs/DB06196ApprovedInvestigational[A4017,A263046] Icatibant was approved by the FDA on August 25, 2011, and by the EMA in 2008 as a treatment for hereditary angioedema. … swelling, thus demonstrating bradykinin involvement in the disease pathophysiology.
Categories: Drugs Used in Hereditary AngioedemaProducts: ICATIBANT EG, Icatibant STADA 30 mg Injektionslösung in einer FertigspritzeTrospium
go.drugbank.com/drugs/DB00209ApprovedInvestigational[L6208] An overactive bladder leads to an increased urge to urinate, frequent urination, and sometimes, loss of control over urination. … [L6208] Trospium is manufactured by _Indevus Pharmaceutical Inc._ and was granted FDA approval in 2007.[L6211]
Products: Trospium Chloride ERSilodosin
go.drugbank.com/drugs/DB06207ApprovedInvestigational[A231159] Silodosin was first approved by the FDA in October 2008 [A231159] and it is also approved in Europe and Canada. … It is indicated for the symptomatic treatment of benign prostatic hyperplasia in adults.
Categories: Drugs Used in Benign Prostatic HypertrophyProducts: SILODOSINA EGDarifenacin
go.drugbank.com/drugs/DB00496ApprovedInvestigationalThis block reduces the urgency to urinate and so it should not be used in people with urinary retention. … It is unknown if M3 receptor selectivity is clinically advantageous in overactive bladder syndrome treatments.
Products: DARUCIL® ER 15 MGLevetiracetam
go.drugbank.com/drugs/DB01202ApprovedInvestigationalIt was first approved for use in the United States in 1999 and is structurally and mechanistically unrelated to other anti-epileptic drugs (AEDs). … interactions[L8606,L8600,L8615] - these characteristics make it a desirable choice over other AEDs, a class of drugs notorious for having generally narrow therapeutic indexes and a propensity for involvement in
Products: Levetiracetam ER, LEVETIRACETAM EGCyclobenzaprine
go.drugbank.com/drugs/DB00924ApprovedInvestigationalCyclobenzaprine, a centrally-acting muscle relaxant, was first synthesized in 1961[A185039] and has been available for human use since 1977. … [A185039,A184982] Since its approval, it has remained relatively popular as an adjunctive, short-term treatment for acute skeletal muscle spasms secondary to musculoskeletal injury.
Synonyms: N,N-dimethyl-5H-dibenzo(a,d)cycloheptene-Δ5,γ-propylamineProducts: Cyclobenzaprine HCL ERTrimipramine
go.drugbank.com/drugs/DB00726ApprovedInvestigationalTricyclic antidepressant similar to imipramine, but with more antihistaminic and sedative properties.
Synonyms: 10,11-dihydro-N,N,β-trimethyl-5H-dibenz[b,f]azepine-5-propanamineProducts: TRIMINEURIN 40 MG/ML Z EIN